HuGE Literature Finder
Records
1
-
6
Effects of CYP2D6 and CYP3A5 genetic polymorphisms on steady-state pharmacokinetics and hemodynamic effects of tamsulosin in humans. European journal of clinical pharmacology 2018 Jun . Kim Kyoung-Ah, Park In-Bae, Park Ji-You |
Genetic variants in 5p13.2 and 7q21.1 are associated with treatment for benign prostatic hyperplasia with the a-adrenergic receptor antagonist. The aging male : the official journal of the International Society for the Study of the Aging Male 2017 Aug 1-7. Qian Xiaoqiang, Xu Ding, Liu Hailong, Lin Xiaoling, Yu Yongjiang, Kang Jian, Sheng Xujun, Xu Jianfeng, Zheng Siqun, Xu Danfeng, Qi J |
ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients. European journal of clinical pharmacology 2013 Mar 69 (3): 385-93. García Montserrat, Macías Rosa María, Cubero Juan José, Benítez Julio, Caravaca Francisco, Gervasini Guiller |
The influence of UGT2B7, UGT1A8, MDR1, ALDH, ADH, CYP3A4 and CYP3A5 genetic polymorphisms on the pharmacokinetics of silodosin in healthy Chinese volunteers. Drug metabolism and pharmacokinetics 2012 Dec . Wang Z, Xiang Q, Cui Y, Zhao X, Zhou Y |
Joint effects of inflammation and androgen metabolism on prostate cancer severity. International journal of cancer. Journal international du cancer 2008 Sep 123 (6): 1385-9. Rebbeck Timothy R, Rennert Hanna, Walker Amy H, Panossian Saarene, Tran Teo, Walker Kyle, Spangler Elaine, Patacsil-Coomes Margerie, Sachdeva Rajeev, Wein Alan J, Malkowicz S Bruce, Zeigler-Johnson Charni |
The androgen receptor CAG repeat length polymorphism associates with prostate volume in Finnish men with benign prostatic hyperplasia. DNA and cell biology 2008 Feb 27 (2): 109-13. Renko Outi, Savolainen Eeva-Riitta, Loikkanen Ildikó, Paavonen Timo K, Vaarala Markku |
- Page last reviewed:Jul 25, 2022
- Page last updated:Jan 27, 2023
- Content source: